Faktor Risiko Non-genetik Inhibitor Faktor VIII pada Pasien Hemofilia A

Ahmad Saifudin, Harry Raspati Achmad, Lelani Reniarti

Sari


Latar belakang. Terbentuknya inhibitor atau antibodi terhadap FVIII pada pasien hemofilia A menyebabkan FVIII eksogen yang
diberikan tidak dapat berfungsi. Penyebab bersifat multifaktorial terdiri atas faktor genetik dan lingkungan. Beberapa penelitian telah
dilakukan untuk mengetahui faktor risiko terbentuknya inhibitor, akan tetapi masih terdapat pendapat yang kontroversial.
Tujuan. Menentukan faktor risiko non-genetik inhibitor faktor VIII pada pasien hemofilia A.
Metode. Penelitian desain potong lintang pada pasien hemofilia A yang terdaftar pada Himpunan Masyarakat Hemofilia Jawa
Barat dari bulan Desember 2012–Juni 2013. Analisis bivariat dilakukan dengan uji chi-kuadrat dan uji t.
Hasil. Terdapat 85 pasien hemofilia A yang mendapat terapi koate®. Prevalensi inhibitor 81,13% (69/85), usia inhibitor positif
9,96 (6,49) tahun dan inhibitor negatif 8,69 (3,87) tahun. Hubungan faktor risiko usia pertama kali mendapat terapi, jenis
hemofilia A, riwayat operasi, dan frekuensi terapi dengan inhibitor faktor VIII pada pasien hemofilia A berturut-turut adalah
p=0,512; p=0,202; p=0,663; p=0,276.
Kesimpulan. Faktor risiko non-genetik tidak berhubungan dengan inhibitor faktor VIII pada pasien hemofilia A.


Kata Kunci


faktor risiko non-genetik; hemofilia A; inhibitor faktor VIII

Teks Lengkap:

PDF

Referensi


Giordano P, Franchini M, Lassandro G, Faienza MF,

Valente R, Molinari AC. Issues in pediatric haemophilia

care. Italian J Pediatr 2013;39:1–5.

The World Federation of Hemophilia. Diagnosis and

management of inhibitors to factor VIII and IX: an

introductory discussion for physicians. California: The

World Federation of Hemophilia; 2004.

Gringeri A, Mantovani LG, Scalone L, Mannucci

PM. Cost of care and quality of life for patients with

hemophilia complicated by inhibitors: the COCIS Study

Group. Blood 2003;102:2358–63.

Morfini M, Haya S, Tagariello G. European study

on orthopaedic status of haemophilia patients with

inhibitors. Haemophilia 2007;13:606–12.

DiMichele DM. Inhibitors in childhood hemophilia

A: genetic and treatment-related risk factors for

development and eradication. Pediatr Blood Cancer

;60:30–3.

Astermark J, Altisent C, Batorova A, Diniz M,

Gringer A, Holme P, dkk. Non-genetic risk factors

and the development of inhibitors in haemophilia: a

comprehensive review and consensus report. Haemophilia

;16:747–66.

Ragni MV, Ojeifo O, Feng J, Yan J, Hill KA, Sommer

SS, dkk. Risk factors for inhibitor formation in

hemophilia: a prevalent case-control study. Haemophilia

;15:1–8.

Chambost H. Assesing risk factors: prevention of inhibitors

in haemophilia. Haemophilia 2010;16:10–5.

Astermark J. Inhibitor development: patient-determined

risk factors. Haemophilia 2010;16:66–70.

Simatupang GNA, Windiastuti E, Oswari H. faktor

risiko timbulnya inhibitor faktor VIII. Sari Pediatri

;15:320–6.

Harijadi, Gatot D, Akib A. The prevalence of factor

VIII inhibitor in patients with severe hemophilia A

and its clinical characteristics. Paeditica Indonesiana2005;45:171–81.

Hay CR, Palmer B, Chalmers E, Liesner R, Maclean R,

Rangarajan S, dkk. Incidence of factor VIII inhibitors

throughout life in severe hemophilia A in the United

Kingdom. Blood 2011;117:6367–70.

Gouw SC, Bom JGvd, Ljung R, Escuriola C, Cid AR,

Donadel SC, dkk. Factor VIII products and inhibitor

development in severe hemophilia A. N Engl J Med

;386:231-9.

Maclean P, Richards M, Williams M, Collins P, Liesner R,

Keeling D, dkk. Treatment related factors and inhibitor

in children with severe hemophilia A. Haemophilia

;17:282–7.

Santagostino E, Mancuso M, Rocino A. Environmental

risk factors for inhibitor development in children with

hemophilia A: a case-control study. British J Haematol

;130:422-7.

Van der Bom J, Mauser-Buncschoten E, Fischer K, Van

der Berg H. Age at first treatment and immune tolerance

to factor VIII in severe hemophilia. Thromb Haemost

;89:46-51.

Gouw SC, Bom JGvd, Berg Mvd. Treatment-related risk

factors of inhibitor development in previously untreated

patients with hemophilia A: the CANAL cohort study.

Blood 2007;109:4648–54.

Kruse-Jarres R. Current controversies in the formation

and treatment of alloantibodies to factor VIII in

congenital haemophilia A. Hematology 2011:407–12.

Goudemmand J, Rothschild C, Deminguel V, Vinciguerrat

C, Lambert T, Chambost H, et al. Influence of the type

of factor VIII concentrate on the incidence of factor VIII

inhibitors in previously untreated patients with severe

hemophilia A. Blood 2006;107:46–51.

Chalmers EA, Brown SA, Keeling D, Et.al. Early factor

VIII exposure and subsequent inhibitor development

in children with severe haemophilia A. Haemophilia

;13:149-55.

Dimichele DM. Inhibitors in haemophilia: a primer.

World Federation of Haemophilia 2008;7:1–4.




DOI: http://dx.doi.org/10.14238/sp17.2.2015.119-23

Refbacks

  • Saat ini tidak ada refbacks.


##submission.copyrightStatement##

##submission.license.cc.by-nc-sa4.footer##

Informasi Editorial:
Badan Penerbit Ikatan Dokter Anak Indonesia
Jl. Salemba I No 5, Jakarta 10430, Indonesia
Phone/Fax: +62-21-3912577
Email: editorial [at] saripediatri.org

Lisensi Creative Commons
Sari Pediatri diterbitkan oleh Badan Penerbit Ikatan Dokter Anak Indonesia
Ciptaan disebarluaskan di bawah Lisensi Creative Commons Atribusi-NonKomersial-BerbagiSerupa 4.0 Internasional.